HK1055956A1 - Macroheterocylic compounds useful as kinase inhibitors - Google Patents

Macroheterocylic compounds useful as kinase inhibitors

Info

Publication number
HK1055956A1
HK1055956A1 HK03108227A HK03108227A HK1055956A1 HK 1055956 A1 HK1055956 A1 HK 1055956A1 HK 03108227 A HK03108227 A HK 03108227A HK 03108227 A HK03108227 A HK 03108227A HK 1055956 A1 HK1055956 A1 HK 1055956A1
Authority
HK
Hong Kong
Prior art keywords
compounds useful
macroheterocylic
kinase inhibitors
kinase
dual
Prior art date
Application number
HK03108227A
Other languages
English (en)
Inventor
Gee-Hong Kuo
Catherine Prouty
Alan Deangelis
Han-Cheng Zhang
Peter Conolly
William V Murray
Chandra R Shah
Bruce E Maryoff
Kimberly B White
Shen Lan
Bruce Conway
Keith Demarest
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of HK1055956A1 publication Critical patent/HK1055956A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
HK03108227A 2000-12-08 2003-11-12 Macroheterocylic compounds useful as kinase inhibitors HK1055956A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25416100P 2000-12-08 2000-12-08
PCT/US2001/047866 WO2002046197A1 (en) 2000-12-08 2001-12-06 Macroheterocylic compounds useful as kinase inhibitors

Publications (1)

Publication Number Publication Date
HK1055956A1 true HK1055956A1 (en) 2004-01-30

Family

ID=22963161

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03108227A HK1055956A1 (en) 2000-12-08 2003-11-12 Macroheterocylic compounds useful as kinase inhibitors

Country Status (12)

Country Link
US (1) US6828327B2 (xx)
EP (1) EP1345946B1 (xx)
JP (1) JP2004526676A (xx)
AT (1) ATE301661T1 (xx)
AU (2) AU2002227371B2 (xx)
CA (1) CA2431187A1 (xx)
DE (1) DE60112611T2 (xx)
ES (1) ES2245994T3 (xx)
HK (1) HK1055956A1 (xx)
MX (1) MXPA03005139A (xx)
RU (1) RU2275373C2 (xx)
WO (1) WO2002046197A1 (xx)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003076442A1 (en) 2002-03-05 2003-09-18 Eli Lilly And Company Purine derivatives as kinase inhibitors
CN1639152A (zh) 2002-03-08 2005-07-13 伊莱利利公司 吡咯－2,5－二酮衍生物及其作为gsk－3抑制剂的用途
ATE387444T1 (de) * 2002-05-08 2008-03-15 Janssen Pharmaceutica Nv Substituierte pyrroline als kinase inhibitoren
TWI324604B (en) * 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
US20090155266A1 (en) * 2004-01-16 2009-06-18 Yale University Methods and Compositions Relating to Vascular Endothelial Growth Factor and TH2 Mediated Inflammatory Diseases
US20070282016A1 (en) * 2004-09-17 2007-12-06 Jenrow Kenneth A Methods and compositions for use of angiogenesis inhibitors in the prevention and/or control of epilepsy
US8017395B2 (en) 2004-12-17 2011-09-13 Lifescan, Inc. Seeding cells on porous supports
SI1888123T1 (sl) 2005-06-08 2013-04-30 Janssen Biotech, Inc. Celična terapija za okularno degeneracijo
CA2624378A1 (en) * 2005-09-29 2007-04-12 Janssen Pharmaceutica N.V. Macroheterocylic compounds as kinase inhibitors
CA2645289A1 (en) * 2006-03-10 2007-09-20 Janssen Pharmaceutica, N.V. Pyridine-containing macroheterocylic compounds as kinase inhibitors
US8741643B2 (en) 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
CN101558062A (zh) * 2006-12-19 2009-10-14 诺瓦提斯公司 作为激酶抑制剂的吲哚基马来酰亚胺衍生物
US9080145B2 (en) 2007-07-01 2015-07-14 Lifescan Corporation Single pluripotent stem cell culture
RU2473685C2 (ru) 2007-07-31 2013-01-27 Лайфскен, Инк. Дифференцировка человеческих эмбриональных стволовых клеток
CN101878298B (zh) 2007-11-27 2017-08-15 生命扫描有限公司 人胚胎干细胞的分化
EP2238142B1 (en) 2007-12-24 2012-07-04 Janssen R&D Ireland Macrocyclic indoles as hepatitis c virus inhibitors
CN105886459A (zh) 2008-02-21 2016-08-24 詹森生物科技公司 用于细胞粘附、培养和分离的方法、表面改性培养板和组合物
US8623648B2 (en) 2008-04-24 2014-01-07 Janssen Biotech, Inc. Treatment of pluripotent cells
KR101829310B1 (ko) 2008-06-30 2018-02-14 얀센 바이오테크 인코포레이티드 만능 줄기 세포의 분화
AU2009281138B2 (en) * 2008-08-14 2014-03-27 Tibotec Pharmaceuticals Macrocyclic indole derivatives useful as hepatitis C virus inhibitors
ES2634445T3 (es) 2008-10-31 2017-09-27 Janssen Biotech, Inc. Diferenciación de las células madre embrionarias humanas con el linaje endocrino pancreático
EP2350265B1 (en) 2008-10-31 2019-04-17 Janssen Biotech, Inc. Differentiation of human embryonic stem cells to the pancreatic endocrine lineage
JP5719305B2 (ja) 2008-11-20 2015-05-13 ヤンセン バイオテツク，インコーポレーテツド 平面支持体上での細胞付着及び培養のための方法及び組成物
US20100124781A1 (en) 2008-11-20 2010-05-20 Shelley Nelson Pluripotent Stem Cell Culture on Micro-Carriers
CN102482640B (zh) 2009-07-20 2015-03-11 詹森生物科技公司 人胚胎干细胞的分化
RU2579278C2 (ru) 2009-07-20 2016-04-10 Янссен Байотек, Инк. Популяция панкреатических эндокринных клеток-предшественников для снижения концентрации глюкозы в крови и способ дифференцировки панкреатических эндодермальных клеток
CN102597219B (zh) 2009-07-20 2015-08-19 詹森生物科技公司 人胚胎干细胞的分化
US20120208750A1 (en) 2009-09-29 2012-08-16 Joslin Diabetes Center, Inc. Use of protein kinase c delta (pkcd) inhibitors to treat diabetes, obesity, and hepatic steatosis
CA2784415C (en) 2009-12-23 2019-06-18 Jean Xu Differentiation of human embryonic stem cells
EP2516626B1 (en) 2009-12-23 2017-05-10 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
TWI507462B (zh) * 2010-01-25 2015-11-11 羅門哈斯電子材料有限公司 包含有含氮化合物之光阻
JP5902103B2 (ja) * 2010-02-22 2016-04-13 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート プロテインキナーゼｃイプシロン（ｐｋｃ−イプシロン）タンパク質レベルの、アルツハイマー病に特異的な変化
CN102791851B (zh) 2010-03-01 2017-07-14 詹森生物科技公司 纯化衍生自多能干细胞的细胞的方法
EP3498825A1 (en) 2010-05-12 2019-06-19 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
CA2809305C (en) 2010-08-31 2019-06-11 Janssen Biotech, Inc. Differentiation of pluripotent stem cells
SG10201506855RA (en) 2010-08-31 2015-10-29 Janssen Biotech Inc Differentiation of human embryonic stem cells
BR112013004514A2 (pt) 2010-08-31 2016-06-07 Janssen Biotech Inc diferenciação das células-tronco embrionárias humanas
CA2857374A1 (en) 2011-09-02 2013-03-07 The Trustees Of Columbia University In The City Of New York Camkii, ip3r, calcineurin, p38 and mk2/3 inhibitors to treat metabolic disturbances of obesity
RU2705001C2 (ru) 2011-12-22 2019-11-01 Янссен Байотек, Инк. Дифференцировка эмбриональных стволовых клеток человека в одногормональные инсулинположительные клетки
EP2823037A4 (en) 2012-03-07 2015-09-16 Janssen Biotech Inc DEFINED MEDIA FOR THE EXPANSION AND CARE OF PLURIPOTENTAL STEM CELLS
AU2013271581B2 (en) 2012-06-08 2018-08-09 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endocrine cells
CA2896750A1 (en) 2012-12-31 2014-07-03 Janssen Biotech, Inc. Suspension and clustering of human pluripotent cells for differentiation into pancreatic endocrine cells
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
WO2014105543A1 (en) 2012-12-31 2014-07-03 Janssen Biotech, Inc. Culturing of human embryonic stem cells at the air-liquid interface for differentiation into pancreatic endocrine cells
BR112015015701A2 (pt) 2012-12-31 2017-07-11 Janssen Biotech Inc diferenciação de células-tronco embrionárias humanas em células pancreáticas endócrinas com o uso de reguladores hb9
DK3143127T3 (da) 2014-05-16 2021-09-13 Janssen Biotech Inc Anvendelse af små molekyler til at forstærke mafa-ekspression i endokrine pankreasceller
WO2017004342A1 (en) 2015-07-02 2017-01-05 Tp Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
MX2018000718A (es) * 2015-07-21 2020-01-20 Turning Point Therapeutics Inc Macrociclos de diarilo quirales y usos de los mismos.
RU2630958C2 (ru) * 2015-12-29 2017-09-15 федеральное государственное автономное образовательное учреждение высшего образования "Московский физико-технический институт (государственный университет)" (МФТИ) Новые макроциклические соединения, содержащие природное 3,7-диазабицикло[3.3.1]нонановое ядро и способ их получения
MA45479A (fr) 2016-04-14 2019-02-20 Janssen Biotech Inc Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
WO2018183703A1 (en) 2017-03-31 2018-10-04 NeuroDiagnostics LLC Lymphocyte-based morphometric test for alzheimer's disease
US20200113979A1 (en) * 2017-06-12 2020-04-16 Temple University-Of The Commonwealth System Of Higher Education Protein Kinase C-delta targeted therapy for treating radiation injury
US11286264B2 (en) 2017-07-28 2022-03-29 Turning Point Therapeutics, Inc. Macrocyclic compounds and uses thereof
PL3728271T3 (pl) 2017-12-19 2023-01-23 Turning Point Therapeutics, Inc. Związki makrocykliczne do leczenia chorób
US20220133740A1 (en) 2019-02-08 2022-05-05 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589472A (en) * 1992-09-25 1996-12-31 Vice; Susan F. Diindolo compounds and pharmaceutical compositions containing them
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
RU2147304C1 (ru) * 1993-12-07 2000-04-10 Эли Лилли Энд Компани Бис-индолмалеимидные макроциклические производные, способ их получения (варианты) и фармацевтическая композиция
BR9709301A (pt) 1996-05-01 1999-08-10 Univ Mississipi Inibidores da proteína quinase c halo-substituídos
US6093713A (en) 1997-12-31 2000-07-25 Kyowa, Hakko, Kogyo Co., Ltd. 3'-epimeric K-252A derivatives
GB9828640D0 (en) 1998-12-23 1999-02-17 Smithkline Beecham Plc Novel method and compounds

Also Published As

Publication number Publication date
CA2431187A1 (en) 2002-06-13
EP1345946A1 (en) 2003-09-24
AU2737102A (en) 2002-06-18
DE60112611T2 (de) 2006-06-14
AU2002227371B2 (en) 2007-05-10
MXPA03005139A (es) 2004-01-29
DE60112611D1 (de) 2005-09-15
ATE301661T1 (de) 2005-08-15
ES2245994T3 (es) 2006-02-01
WO2002046197A1 (en) 2002-06-13
US20030078280A1 (en) 2003-04-24
US6828327B2 (en) 2004-12-07
EP1345946B1 (en) 2005-08-10
JP2004526676A (ja) 2004-09-02
RU2275373C2 (ru) 2006-04-27

Similar Documents

Publication Publication Date Title
AU2737102A (en) Macroheterocylic compounds useful as kinase inhibitors
HK1057370A1 (en) Indazolyl-substituted pyrroline compounds as kinase inhibitors
AU2003240517A1 (en) Substituted pyrrolines as kinase inhibitors
AU2003225295A1 (en) Substituted pyrroline kinase inhibitors
HK1057373A1 (en) Substituted triazole diamine derivatives as kinaseinhibitors
MXPA02005844A (es) Inhibidores de cinasas de proteina.
AU8112101A (en) Non-imidazole aryloxypiperidines
AU3831301A (en) Method for treating ocular pain
HK1052940A1 (en) Synthetic methods for aplidine and new antitumoralderivatives, methods of making and using them
GB0011358D0 (en) Novel use
AP2001002248A0 (en) Method for treating COPD.
MXPA04000446A (es) 4-aminociclohexanoles sustituidos.
MXPA02011762A (es) Proceso para la preparacion de compuestos metales de transicion y su empleo para la polimerizacion de olefinas.
MXPA04000272A (es) Derivados de 4-aminociclohexanol sustituidos.
IT1317942B1 (it) Composizione per il trattamento di dermatiti ed eczemi.
UA49490A (uk) Спосіб лікування ревматоїдного артриту
WO2007041195A3 (en) Macroheterocylic compounds as kinase inhibitors

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20191208